Form 4: Milestone Pharma CCO Reports Stock Transactions

Milestone Pharmaceuticals' Chief Commercial Officer, Lorenz Muller, reported recent acquisitions of common shares through PSU and RSU vesting, along with sales to cover tax liabilities, and a new stock option grant.

Summary

• Lorenz Muller, Chief Commercial Officer of Milestone Pharmaceuticals Inc. (MIST), reported several transactions.
• On December 12, 2025, Muller acquired 100,000 common shares through the vesting of a performance stock unit (PSU) award, triggered by the U.S. Food and Drug Administration's (FDA) approval of Cardamyst (etripamil).
• Also on December 12, 2025, Muller was granted 100,000 employee stock options with an exercise price of $1.74, with 50% vesting on June 12, 2026, and the remaining 50% on December 12, 2026.
• On December 15, 2025, Muller sold 53,566 common shares at a weighted average price of $2.32 per share to satisfy income tax liabilities related to the PSU vesting.
• On January 26, 2026, Muller acquired 20,100 common shares through the vesting of restricted stock unit (RSU) awards.
• On January 26, 2026, Muller sold 11,180 common shares at a weighted average price of $1.93 per share to satisfy income tax liabilities related to the RSU vesting.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant milestone of FDA approval for Cardamyst, which triggered PSU vesting. This positive is somewhat offset by the insider sales, though these were for tax purposes and pre-planned, which is a neutral event.

Positives

• Vesting of 100,000 performance stock units (PSUs) on December 12, 2025, was triggered by the U.S. FDA's New Drug Application Approval Letter for Cardamyst (etripamil), indicating a significant regulatory milestone for the company.
• Grant of 100,000 employee stock options on December 12, 2025, with an exercise price of $1.74, aligning management incentives with shareholder value.
• Vesting of 20,100 restricted stock units (RSUs) on January 26, 2026, as part of the compensation plan.

Negatives

• Sales of 53,566 common shares at $2.32 on December 15, 2025, and 11,180 common shares at $1.93 on January 26, 2026, were conducted to cover income tax liabilities, which reduces the insider's direct ownership.

Future Outlook

Future vesting events include 50% of the granted employee stock options on June 12, 2026, and the remaining 50% on December 12, 2026. Additionally, one-fourth of the RSU award shares will vest annually on January 26, from 2027 through 2029.

Industry Context

The vesting of performance stock units (PSUs) upon FDA approval of Cardamyst (etripamil) is a significant event for Milestone Pharmaceuticals, a company in the biotechnology and pharmaceutical sector. FDA approval is a critical milestone for drug development companies, validating their research and development efforts and opening pathways for commercialization. This event positions Cardamyst for market entry, potentially enhancing the company's competitive standing in its therapeutic area.

Stakeholder Impact

• Shareholders: The FDA approval of Cardamyst is a positive development, potentially increasing the company's value. Insider transactions, even for tax purposes, provide transparency into management's holdings.
• Employees: The vesting of PSUs and RSUs, and the grant of stock options, are part of employee compensation plans, aligning their interests with company performance.

Next Steps

• Continued vesting of employee stock options on June 12, 2026, and December 12, 2026.
• Continued vesting of restricted stock units (RSUs) annually on January 26, from 2027 through 2029.
• Commercialization efforts for Cardamyst (etripamil) following FDA approval.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Form 4, Insider Trading, Lorenz Muller, Chief Commercial Officer, Stock Options, Restricted Stock Units, Performance Stock Units, Cardamyst, Etripamil, FDA Approval, Rule 10b5-1, Biotechnology, Pharmaceuticals